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Introduction
Squamous cell carcinoma (SCC) is a type of cancer caused 
by uncontrolled proliferation of squamous cells. SCCs are 
one of the most prevalent malignancies, arising in diverse 
body sites such as skin, mouth, esophagus, lung, and cervix. 
Of them, head and neck SCC (HNSCC) is the sixth leading 
malignancy globally [1], whereas cutaneous SCC (CSCC) 
is the second most common skin cancer worldwide [2].
Notch homolog 1, translocation associated (Drosophila), 
also known as NOTCH1, is a human gene encoding a 
single- pass transmembrane receptor. Notch signaling path-
ways play a key role in development and tissue homeostasis, 
and its dysfunction is involved in tumorigenesis and other 
human diseases [3]. However, Notch signaling activation 
can be tumor suppressive or oncogenic, depending on cel-
lular context [4]. Recently, considerable NOTCH gene 
mutations were identified in different types of squamous 
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Abstract
The role of Notch pathway in tumorigenesis is highly variable. It can be tumor 
suppressive or pro- oncogenic, typically depending on the cellular context. Squa-
mous cell carcinoma (SCC) is a cancer of the squamous cell, which can occur 
in diverse human tissues. SCCs are one of the most frequent human malignan-
cies for which the pathologic mechanisms remain elusive. Recent genomic analysis 
of diverse SCCs identified marked levels of mutations in NOTCH1, implicating 
Notch signaling pathways in the pathogenesis of SCCs. In this review, evidences 
highlighting NOTCH’s role in different types of SCCs are summarized. Moreover, 
based on accumulating structural information of the NOTCH receptor, the 
functional consequences of NOTCH1 gene mutations identified from diverse 
SCCs are analyzed, emphasizing loss of function of Notch in these cancers. 
Finally, we discuss the convergent view on an intriguing possibility that Notch 
may function as tumor suppressor in SCCs across different tissues. These mecha-
nistic insights into Notch signaling pathways will help to guide the research of 
SCCs and development of therapeutic strategies for these cancers.
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cell carcinoma [5–9], questioning the general role of Notch 
pathway in SCCs.
In this review, evidences highlighting the role of Notch 
in different SCCs are summarized. In particular, we explored 
the NOTCH1 mutation patterns in different SCCs, analyzed 
their functional consequence based on current structural 
model of the Notch receptor. We suggest that most of the 
NOTCH1 gene alterations are loss- of- function mutations. 
We discuss the intriguing possibility that a tumor suppres-
sor role of Notch may be appreciated across diverse SCCs. 
The insights gathered from separate SCCs may have com-
plementary advantages toward clearer understanding of 
Notch’s role involved in squamous cell carcinogenesis.
Notch Signaling
Notch signaling is a highly conserved signaling pathway in 
metazoan. It plays essential roles in multiple stages of meta-
zoan development and tissue renewal. Its dysregulation is 
participated in a number of human diseases such as cancers 
and developmental disorders [10, 11].
NOTCH receptors are type I single- pass membrane pro-
teins. From Drosophila to mammals, the Notch homologues 
share highly conserved domain architecture [3]. The large 
Notch extracellular domain (NECD) comprises 11–36 tan-
demly repeated epidermal growth factor- like (EGF) repeats 
followed by a negative regulatory region (NRR) composed 
of three Lin12- Notch repeats (LNR) and a hetero- 
dimerization domain (HD). The HD domain is cleaved at 
S1 site by a furin- like protease within the secretory pathway 
[12], generating a heterodimer that remains in a resting 
state, with its NRR domain being resistant to further 
 protease cleavage [13, 14].
The activation of Notch pathway usually involves the 
direct interaction between Notch and its ligands on cell 
surface (Fig. 1). Previous work demonstrated that EGF11 
and EGF12 are the required elements for Notch1 to be 
able to recognize its ligands Jagged and DLL [15]. Ligand 
binding leads to the cleavage at the juxtamembrane region 
(site S2) of Notch by ADAM (a disintegrin and metallo-
protease) protease [16, 17]. Shedding of the Notch extracel-
lular domain facilitates subsequent intramembranous 
cleavage of Notch by γ- secretase complex, generating Notch 
intracellular domain (NICD or ICN)[18, 19]. The NICD 
mainly contains membrane- proximal RAM domain, an 
ANK domain, and C- terminal PEST motif [3]. The NICD 
migrates to the nucleus and associates at high affinity with 
DNA- binding factor CSL through the RAM domain [20]. 
Meanwhile, the ANK domain weakly interacts with both 
CSL and a shorter sequence at the N- terminal end of 
mastermind- like 1 (MAML1) protein (the transcriptional 
co- activator)[21, 22]. The formed transcription activation 
ternary complex NICD/CSL/MAML1 further upregulates 
the target genes (such as HES/HEY transcriptional repres-
sors [23]), which is known as the canonical Notch signaling 
pathway [3].
Notch Signaling in Cutaneous 
Squamous Cell Carcinoma (CSCC)
Prevalent evidences support the notion that Notch activa-
tion can be growth repressive and differentiation inducing 
in CSCC. However, the detailed molecular mechanism 
underlying these effects remains not to be clearly 
elucidated.
Genomic characterization of NOTCH in CSCC
Whole- exome or NOTCH1/NOTCH2 exons sequencing of 
primary CSCC or CSCC cell lines identified NOTCH1 or 
NOTCH2 mutations in ~75% of samples tested [5]. The 
missense mutations were found to be localized to NECD 
EGF- like repeats, NECD HD domain, and the intracellular 
RAM domain. In particular, selected missense mutations 
were further characterized to be loss- of- function mutations. 
Specifically, D469G from EGF- like repeat domain and 
R1594Q from the NECD LNR- C domain significantly 
reduced ligand- mediated NOTCH1 activation, whereas 
P1770S from the RAM domain seems to interfere with 
Notch signaling at the level of transcription complex assem-
bly. Furthermore, high- frequent mutation of NOTCH in 
Figure 1. The canonical Notch signaling pathway. The interaction 
between Notch and its ligands from neighboring cells results in two 
successive cleavage event: cleavage at site S2 by ADAM protease and 
subsequent intramembranous cleavage at S3 by γ- secretase complex. 
This ligand- dependent activation process generates Notch intracellular 
domain (NICD). In the nucleus, NICD forms the transcription activation 
complex with transcription factor CSL and transcriptional coactivator 
such as MAML1, initiating the transcription of target genes.
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CSCC was confirmed by exome or targeted sequencing of 
CSCCs or squamoproliferative lesions [24, 25].
Reduced notch levels in CSCC
Besides mutations, reduced NOTCH levels or activation 
observed in CSCC also support its tumor suppressor role. 
Decreased levels of NOTCH transcript and protein together 
with a parallel reduction in HES1 gene (a common target 
of Notch pathway) were observed in CSCC cell lines [26]. 
Furthermore, reduced levels of activated NOTCH1 were 
detected in CSCC, correlating with their NOTCH1 muta-
tion status [24]. Protein and transcript levels of NOTCH1 
were also found to be decreased in human CSCCs compared 
with nonlesional epidermis [27].
Effects of NOTCH loss of function in CSCC
The functional consequences of attenuated Notch signaling 
in CSCC or keratinocyte (KC) were well demonstrated by 
several studies on loss of function of NOTCH1 receptor. 
Inhibition of Notch activation in primary keratinocytes by 
the expression of a dominant negative peptide competing 
for MAML1 binding to Notch/CSL complex can cause 
aggressive SCC formation depending on activated ras [26]. 
Consistently, conditional transgenic mice were generated 
by expressing a dominant negative MAML1 protein to 
inhibit Notch signaling in the epidermis. These mice exhib-
ited epidermal hyperplasia and developed spontaneous 
CSCC [28]. Furthermore, the keratinocyte- specific ablation 
of NOTCH1 induced significant proliferation of the basal 
epidermal layer and deregulated expressions of multiple 
differentiation markers, indicating disrupted balance 
between growth and differentiation [29]. In a later research 
using similar conditional gene deletion technology, effects 
of long- term NOTCH1 deficiency were further character-
ized [30]. The induced Notch1-/- adult mice showed epi-
dermal hyperplasia followed by formation of skin tumors.
More functional insights were gained from functional 
or clinical observations utilizing Notch signaling inhibitors. 
In vivo treatment of grafted mice with γ- secretase inhibitor 
DAPT (a pharmacological inhibitor of Notch activation) 
resulted in tumor- promoting effects, depending on onco-
genic ras [26]. A recent clinical Phase III trial of 
Semagacestat, a γ- secretase/Notch inhibitor, was halted in 
part because of an increased risk of skin cancers compared 
with those in the placebo arm [31].
Molecular mechanism of notch in CSCC
Compared with other SCC types, the Notch- related molecular 
mechanism for CSCC is relatively well characterized (Fig. 2). 
The disruption of canonical Notch/CSL/MAML- mediated 
signaling pathways in transgenic mice by expressing epider-
mal DNMAML1 (a pan- Notch inhibitor) resulted in hyper-
plastic epidermis and spontaneously developed CSCC [28]. 
In mouse keratinocytes, cyclin- dependent kinase inhibitor 
p21 was identified as a downstream positive target of 
NOTCH1, where activated NOTCH1 induces p21 expression 
to suppress growth in a CSL- dependent manner [29, 30]. 
p21’s role in tumor suppression was earlier investigated where 
p21 knockout keratinocytes exhibited significant downmodu-
lation of differentiation markers and dramatic increase in 
proliferative potential [32]. The inhibition of Notch signaling 
by genetic methods or by using pharmacological Notch 
inhibitors in human keratinocytes, together with activated 
ras, can cause aggressive SCC formation in grafted mice 
[26]. This is similar to that previously revealed for ras- 
transformed p21 knockout keratinocytes [32], suggesting that 
NOTCH1 and p21 may overlap to perform their tumor 
suppressing functions. However, the general role of p21 
remains to be investigated as p21 levels were selectively 
decreased in a subset of human skin SCCs tested [26], whereas 
in human keratinocytes, activation of NOTCH1 was found 
to lead to modest increase in p21 levels [33].
Notch1’s tumor suppressor role in CSCC may involve 
beta- catenin/Wnt pathway. In the epidermis of induced 
Notch1-/- mice, significantly high levels of free (unphos-
phorylated) beta- catenin were observed [30]. Loss of Notch1 
signaling seems to activate beta- catenin signaling in human 
CSCC [28], which can be repressed by the introduction of 
a dominant active form of NOTCH1[30]. In particular, p21 
(a downstream mediator of Notch1- induced growth arrest 
Figure 2. Tumor suppressive Notch signaling involved in the tumorigenesis 
of CSCC. Inactivation of Notch signaling contributes to CSCC. SFK, Src 
family tyrosine kinases; EGFR, Epidermal growth factor receptor. The 
signaling pathway components and their connections are described in 
detail in section 2.4 ‘Molecular mechanism of Notch in CSCC’.
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as we described above) also contributes to the downregula-
tion of Wnt signaling, which likely account for the decreased 
levels of beta- catenin activation by activated NOTCH1[34]. 
Furthermore, a negative feedback loop involving p63 is 
thought to modulate this pathway in keratinocytes. p63 is 
essential for maintaining the proliferative potential in epi-
dermal stem cells [33, 35]. NOTCH1 was shown to down-
modulate p63 expression. On the other hand, p63 appears 
to function as a direct repressor of several Notch- modulated 
genes as p63 knockdown led to substantially increased p21 
expression and reduced Wnt signaling [33].
Caspase 3, involved in programmed cell death, was iden-
tified as another downstream mediator of NOTCH. Lack 
of caspase 3 resulted in increased proliferation and 
decreased differentiation of embryonic keratinocytes [36]. 
However, the possible involvement of this pathway in CSCC 
remains to be clarified, although increased expression of 
survivin, an apoptosis inhibitor targeting caspase 3 and 
caspase 7, was observed in CSCC tumors [37–39].
p53 was characterized as a upstream positive regulator 
of NOTCH1. p53 is also an established cancer gene in 
CSCC [40–42] and HNSCC [43]. Although p53 levels in 
cutaneous SCC are less characterized, somatic mutations 
of TP53 are frequently found in many typical tumors includ-
ing CSCCs, which is then likely to compromise p53 function 
[44]. In keratinocytes, p53 was proposed as a positive regu-
lator of Notch signaling. Specifically, p53- responsive ele-
ment has been identified in the Notch1 promoter [26, 45, 
46]. Consequently, NOTCH1 expression is upregulated by 
increased p53 in human primary keratinocytes and CSCC 
cell lines [26, 45].
A further connection exists between the p53- Notch1 
pathway and Src family tyrosine kinases (SFK) pathway. 
SFK are known oncogenes [47] and can be downregulated 
by Srcasm [48]. Increased activation of SFK and decreased 
Srcasm levels were reported in CSCC compared with unre-
markable epidermis [27, 49, 50]. It was later reported that 
the transgenic mice with elevated SFK activity spontaneously 
formed CSCC, and cutaneous neoplasia can be markedly 
inhibited by increasing Srcasm levels [27]. This intriguing 
study showed that increased SFK activity decreases the tran-
script and protein levels of p53 and NOTCH1, thus sug-
gesting another mechanism to control NOTCH1 function.
EGFR was identified as another upstream mechanism 
controlling NOTCH1 function. EGFR is a well- known 
determinant of epithelial cell proliferation. It is frequently 
overexpressed in epithelial tumors [43, 51] and persistently 
activated in keratinocyte tumors [52]. In primary human 
keratinocytes, EGFR signaling suppresses differentiation and 
enhances proliferation by negatively modulating NOTCH1 
transcript and protein levels through p53 [41] in a similar 
way to SFK, suggesting Notch’s central role in CSCC 
development.
Notch Signaling in Head and Neck 
Squamous Cell Carcinoma (HNSCC)
The molecular pathogenesis of HNSCC has not been clari-
fied yet [43]. However, accumulating evidence may suggest 
the crucial role of Notch pathway in HNSCC, possibly in 
a similar manner to that in CSCC.
Genomic characterization of NOTCH in 
HNSCC
In 2011, two independent studies about mutational land-
scape of HNSCC revealed that NOTCH is frequently 
mutated in HNSCC [6, 7]. By whole- exome sequencing of 
74 HNSCC tumor- normal pairs [6], mutations of NOTCH1, 
NOTCH2, and NOTCH3 were identified in 14%, 5%, and 
4% of HNSCC samples. In an independent exome- 
sequencing study of 32 HNSCC primary tumors [7], 
NOTCH1 somatic mutations were identified in 15% of 
patients, and following TP53, NOTCH1 was identified as 
the second most frequently mutated gene. Consistently, early 
this year, a comprehensive genomic characterization of 279 
HNSCCs [53] also revealed frequent NOTCH1 mutations 
(19%). Among the identified mutations, considerable non-
sense or splice- site mutations were revealed which may 
have generated truncation sequences lacking the critical 
regions, while a bunch of missense mutations clustered in 
the NECD ligand- binding region [6, 7], suggesting a tumor 
suppressive role for NOTCH in HNSCC.
Genomic characterization of NOTCH in 
esophageal squamous cell carcinoma (ESCC)
HNSCC patients often develop second ESCC. HNSCC and 
ESCC have some common risk factors and may be closely 
related [54, 55]. Similar mutation pattern of NOTCH1 was 
also revealed by genomic characterization ESCCs [8]. 
Exomic sequencing of 12 ESCCs in parallel with 12 esopha-
geal adenocarcinomas (EAC) revealed frequent NOTCH1 
mutations in 21% of ESCCs but not in EACs [8]. Notably, 
different NOTCH1 alternation patterns were observed in 
patients from different ethnical populations: NOTCH1 
appears to mutate more frequently in North American 
ESCCs (21%) than Chinese ESCCs (2%). However, this 
concept was questioned by a later genetic landscape of 
ESCC samples of Chinese ancestry, which identified a high 
NOTCH (NOTCH1-3) alteration frequency (13%) in 
Chinese cases [56].
Functional characterization of notch 
pathway in HNSCC/ESCC
It was reported that NOTCH1 was downregulated specifi-
cally in squamous neoplasms of oral mucosa and esophagus 
2052 © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
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[57] and was variably reduced in primary oral SCC (OSCC) 
tissues [58]. In another study, mRNA levels of HEY1 (a 
target gene of Notch/CSL/MAML- mediated signaling path-
way) were found to be underexpressed in a subset (26%) 
of ESCC sample, which was significantly correlated with 
tumor depth of invasion [59].
The functional consequences of Notch levels were also 
investigated. Activation of Notch signaling by expressing 
full- length NOTCH1 or its activated form ICN in human 
OSCC or HNSCC cell lines leads to cell growth arrest [9, 
27, 60]. Consistently, inhibition of NOTCH activation 
promoted tumor growth in a HNSCC cell line harboring 
wild- type NOTCH1[27], whereas activation of NOTCH1 
resulted in reduced tumorigenicity in a mouse cancer 
model [9, 27]. Similarly, it was reported that Notch inhi-
bition can promote transdifferentiation of normal esopha-
geal squamous epithelial cells toward a BE (Barrett’s 
esophagus, a precursor of esophageal adenocarcinoma)- like 
metaplasia [61].
Although limited, accumulating evidences related to 
HNSCC/ESCC are consistent with Notch- related molecular 
mechanisms for CSCC (Fig. 2). p21, p53, EGFR, caspase 
3, and beta- catenin/Wnt pathway related to Notch may 
also be involved in generation of HNSCC/ESCC. Activation 
of Notch signaling by stably expressing exogenous NICD 
in human OSCC cell line can lead to growth arrest, accom-
panied by reduced β- catenin expression and dramatic 
increased p21 and p53[60]. EGFR is overexpressed or acti-
vated in premalignant ESCC lesions [62] and is correlated 
with poor prognosis in HNSCC patients [63–67]. Notch 
inhibition by DNMAML1 promotes invasive growth of 
transformed esophageal epithelial cells with EGFR overex-
pression and p53 dysfunction [68]. Moreover, TP53 was 
frequently mutated in HNSCC cases [6, 7, 53], and the 
inactivation of p53 plays important role in HNSCC tumo-
rigenesis [43, 69, 70]. But it has not been clarified yet 
whether Notch signaling is closely involved in this.
Notably, apoptosis dysregulation also seems associated 
with ESCC/OSCC. Expression of survivin, an apoptosis 
inhibitor targeting caspase 3 and caspase 7, was found 
elevated in OSCC tissue [71, 72], whereas caspase 3 expres-
sion level is decreased [72]. Consistently, caspase 3 is found 
associated with a favorable prognosis for primary resected 
ESCC patients [73], whereas survivin expression was pro-
posed as negative prognostic factor of OSCC [74]. However, 
different roles of caspase 3 in OSCC are also suggested. 
Pycnogenol can inhibit neoplastic cell transformation of 
HSC- 3 human OSCC cell, dependent on apoptosis with 
elevated caspase 3 activity [75]. Increased caspase 3 expres-
sion is found in OSCC compared with normal oral epi-
thelium [76]. These findings question the apoptotic role 
of caspase 3, suggesting its nonapoptotic functions in oral 
cancers, as implicated in other cancers [77–79].
Evidences suggesting NOTCH as oncogene in 
HNSCC
However, there are still considerable evidences questioning 
the tumor suppressor role of NOTCH1 in HNSCC. The 
main concern is regarding the elevated levels of Notch 
signaling pathway genes in different HNSCC/ESCC. Notch 
signaling pathway components (including Notch receptors, 
ligands, or targets genes such as HES1, HEY1, or HEY2) 
were found to be amplified or overexpressed in a subset 
of tongue tumor samples [80], in HNSCC tumors over 
normal mucosa [81], in OSCC [82–84], and frequently in 
ESCC samples [85].
However, the functional consequences of Notch pathway 
upregulation have been less characterized. Decreased 
NOTCH1 was associated with the inhibition of cell pro-
liferation in the OSCC cell line [84]. Blocking Notch acti-
vation by gamma- secretase inhibitor can suppress OSCC 
growth in vitro [83] and inhibit the growth of human 
tongue carcinoma cell line [86]. In addition, NOTCH1 was 
also proposed as a poor survival marker in ESCC [87].
Notch Signaling in other Squamous 
Cell Carcinoma
As compared to HNSCC and CSCC, the role of Notch 
signaling in other types of squamous cell carcinoma is 
largely unclear. Evidences are gathered mainly from the 
sequencing research of lung SCC. A comprehensive genomic 
landscape of lung SCC was achieved by whole- genome or 
mRNA sequencing of total 178 lung SCC samples. This 
identified NOTCH1 as one of the significantly mutated 
genes, occurring in 8% of the testing samples. Most of the 
NOTCH1 alterations (8 in 17) were truncating mutations, 
likely causing loss of function [88]. Similarly, an analysis 
of publicly available lung SCC exome- sequencing data 
revealed mutations of NOTCH1 and NOTCH2 at a com-
bined frequency of 12.5% [5].
A Complete View of NOTCH1 
Mutations Across SCCs
Overall NOTCH1 mutation patterns 
across SCCs
To gain insights of Notch alteration across diverse SCCs, 
we summarized publicly available NOTCH1 mutation data 
in five different SCCs (Fig. 3B- F), and analyzed the NOTCH1 
mutation features among them. Considerable nonsense or 
frame- shift mutations occur within or before intracellular 
RAM- ANK domain for transcription regulation, which is 
essential for Notch signaling (Fig. 1). Therefore, these early 
terminations likely result in inactive truncations. In addition, 
large number of missense mutations was also identified, 
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Figure 3. Mutation pattern across diverse SCCs. (A) NOTCH1 mutations identified in tumors of hematopoietic and lymphoid where Notch1 is known 
as oncogene. Gene alteration data are obtained from COSMIC (B) NOTCH1 mutations identified in CSCC [5]. (C- F) NOTCH1 mutations identified in 
HNSCC, esophageal SCC, lung SCC, and cervical SCC, respectively. Gene alteration data are obtained from cBioPortal. In (A) and (B), the mutation 
data are mapped onto Notch1 with cBioPortal tool MutationMapper. The domain organization of Notch1 is labeled under panel (F). Green circles, 
missense mutations; red circles, nonsense or frame- shift mutations. NECD, Notch extracellular domain; NICD, Notch intracellular domain; NRR, 
negative regulatory region; RAM, RBPjκ association module; ANK, ankyrin repeats; PEST, proline/glutamic acid/serine/threonine- rich motif.
A
B
C
D
E
F
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but they cluster within the NECD region with 36 tandem 
EGFs, with a few in the NRR domain or RAM- ANK domain.
This is in contrast to the NOTCH1 alteration pattern 
revealed in hematopoietic malignancies, where Notch is 
known as tumor suppressor [4, 89]. The majority of these 
mutations include missense mutations in the NRR domain 
and nonsense/frame- shift ones in the PEST domain 
(Fig. 3A). Missense mutations in NRR domain likely desta-
bilize inhibitor state of NRR domain, allowing ligand- 
independent Notch activation [90]. PEST domain is 
involved in proteasomal degradation of NOTCH [91, 92], 
and truncations lacking PEST region likely impair the deg-
radation of NOTCH and augment Notch activation.
Functional consequences of NOTCH1 
missense mutations across SCCs
More Compelling evidences for Notch loss of function 
across SCCs may result from the functional consequences 
of the considerable missense mutations. To our knowledge, 
only three mutations identified from CSCC have been 
characterized [5]. To gain more insights into these muta-
tions, we resorted to the accumulating structural knowledge 
of Notch signaling.
Mutations in the RAM- ANK domain
Analysis of the Caenorhabditis elegans (C. elegans) Lin- 12 
RAM- ANK/CSL/Mastermind/DNA complex structure [93] 
(Fig. 4A) shows that P1770 in RAM domain (conserved 
between human and worm, Fig. 4B) inserts into a hydro-
phobic pocket of the transcription factor CSL, thereby 
P1770S is predicted to reduce the binding of NICD to tran-
scription factor. This is consistent with the previously 
reported results [5]. R1784L and R1809H mutations are 
located on the flexible loop, and thus are likely to be benign 
(Fig. 4A). With regards to mutations in ANK domain, map-
ping them onto ANK/CSL/MAML- 1/DNA complex structure 
revealed that they cluster inside the ANK4- 6 motifs (Fig. 4C). 
V2038L and T1996M mutations face bound CSL, and there-
fore likely interfere with the binding of transcription factor. 
A2023T, D2020H, and P2064L mutations are predicted to 
disrupt structure of ANK4- 6 motifs that are involved in 
CSL binding, and therefore likely to be deleterious.
Mutations in the NRR domain
Several mutations were found in the NOTCH1 NRR region. 
Mapping these mutations on the Human NOTCH1 NRR 
crystal structure showed that they cluster in the LNR- B 
and LNR- C domain (Fig. 4D). R1523C may cause cysteine 
crosslink, impairing Notch function. D1517 and D1520 
together with other residues form a Ca2+- binding site 
(Fig. 4E), which is necessary for the stabilization of LNR- B. 
LNR- B is also stabilized by hydrophobic stacking between 
W1487 and W1497. Moreover, there are three disulfide 
bonds around this region. Thus, the mutations in this region 
(W1487C, D1517N, and D1520H) may destabilize LNR- B, 
likely interfering with the correct folding of functional 
Notch1 molecule.
In LNR- C domain, C1561 forms disulfide bond with 
C1545 (Fig. 4F), thus C1561Y likely destabilize the structure 
and the unpaired and solvent- exposed C1545 then probably 
leads to cysteine crosslink between molecules. In addition, 
the R1594Q was previously characterized and shown to be 
a reduced ligand- mediated activation of NOTCH1[5]. A 
very recent structural study of Human NOTCH3 NRR 
domain may provide a basis to understand the effect of a 
glutamine at this position [14]: NOTCH3 has Q1533 at 
this position and the shorter side chain allows the LNR- C 
domain to pack more tightly on HD domain (Fig. 4F), 
likely stabilizing the inhibitory state and decreasing the 
level of Notch activation.
Mutations in the ligand- binding region
EGF11- 12 region of NOTCH1 is the required elements for 
Notch to be able to recognize its ligands Jagged and DLL 
[15]. Quite a few (22 in total) NECD missense mutations 
occur in this small (77 residues) region. In contrast, there 
are no mutations within the neighboring EGF13 that is 
not involved in ligand binding (Fig. 3). Recent structure 
of Rat NOTCH1 EGF11- 13 in complex with its ligand 
DLL4[94] provides a basis to analyze the functional con-
sequence of mutations at this region. Surprisingly, frequent 
mutations (10 out of 22) occur at cysteine positions (Table 1 
and Fig. 4H). The disulfide bonds at these cysteine sites 
are necessary to keep the conserved EGF module structure. 
Thus, these mutations are likely to cause misfolding of 
NOTCH1 to affect Notch function. Similarly, we noticed 
that all the missense mutations on EGF28 occur at cysteine 
sites and they probably disrupt Notch1 folding likewise 
(Table 1 and Fig. 4H). Moreover, the localizations of muta-
tions at noncysteine sites surprisingly showed that they 
cluster near the DLL4 ligand- binding interface of NOTCH1 
EGF11 and EGF12 (Fig. 4G), and therefore are predicted 
to affect Notch ligand binding. G434C and G481C are 
solvent exposed, so they may cause cysteine crosslink to 
affect Notch function. In particular, P422 (Fig. 4I and D469 
(Fig. 4k) mutations are directly involved in ligand binding. 
This can explain the previous finding that D469G showed 
reduced ligand- mediated activation [5]. In addition, E415 
and G434 participate to form a calcium- binding site in 
EGF11 (Fig. 4J). D469 and E455 cooperate with residues 
D452, V453, and D470 to form another calcium- binding 
site in EGF12, with N454 located between them (Fig. 4k). 
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Figure 4. Up- to- date structural information of Notch signaling predicts the deleterious consequences of missense mutations identified in multiple 
SCCs. (A) Ribbon diagrams of the C. elegans transcription activation complex of CSL (blue), Notch RAM- ANK (red), N- terminal domain of Mastermind 
(cyan), and DNA (orange) (pdb id: 2FO1). Mutations in RAM domain of Human NOTCH1 identified in SCCs were mapped onto this complex as blue 
sticks. (B) A close- up view of the marked region in (A) shows the functional consequence of mutation P1770S. Human NOTCH1 P1770 and W1768, 
counterparts of worm Lin- 12 P947 and W945, are labeled in bracket. (C) Mutations in ANK domain of Human NOTCH1 are mapped onto the Human 
complex of CSL (blue), NOTCH1 ANK (red), N- terminal domain of MAML1 (red), and DNA (orange) (pdb id: 2FX8). This zoomed view corresponds to 
the marked area in (A). (D) Mutations in NRR domain of Human NOTCH1 are mapped onto the structure of Human NOTCH1 NRR domain (dark green, 
pdb id: 3ETO). (E) A zoomed view of the marked region in (D). (F) A close- up view of the marked region in (D). The aligned Human NOTCH3 NRR 
domain structure (pdb id: 4ZLP) is shown in magenta. (G) Mutations at noncysteine positions of Human NOTCH1 ligand- binding region (EGF11- 13) 
are mapped onto the Rat NOTCH1 EGF11- 13/DLL4 complex structure (pdb id: 4XLW). (H) Due to the conserved positions of disulfide bonds in EGF 
module, mutations at cysteine positions of Human Notch ligand- binding region (EGF11- 13) and another region (EGF28) are mapped onto the EGF 11 
from (A) to show their relative positions in EGF module. (I- K) Zoomed views of the marked regions in (G).
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A previous mutagenesis study revealed that this calcium- 
binding site is essential for Notch ligand binding [95]. 
Therefore, the E415D, G434C, D469G, N454T, and E455K 
are predicted to affect ligand- mediated activation of Notch 
through the disruption of calcium- binding site.
Conclusions
The role of Notch pathway in tumorigenesis is highly vari-
able. Specifically, it can be tumor suppressive or pro- 
oncogenic, depending on the cellular context [4]. As we 
have described, the tumor suppressor role of Notch was 
relatively well established in CSCC, unlike for HNSCC [43]. 
Until recently, the NOTCH1 has drawn much attention as 
it was identified as one of the most frequently mutated 
genes in SCCs of cutaneous [5], head and neck [6, 7, 53], 
esophageal [8, 56], and lungs [88]. We summarized the 
NOTCH1 mutation patterns in five different SCCs, and 
explored the biological consequences of these mutations 
based on the up- to- date structural information of Notch 
signaling. Our analysis suggested that the Notch loss- of- 
function mutations occur across diverse SCCs. Consistently, 
considerable functional evidences obtained for HNSCC 
suggested substantially overlapped aberrant signaling events 
Table 1. Compilation of NOTCH1 mutations implicated in diverse SCCs and their predicted functional consequences.
Notch1 mutations Positions on Notch1 Predicted functional consequences Associated SCC type
Ligand- binding region
E415D EGF11 Disrupting calcium binding or ligand binding Cutaneous
P422S EGF11 Disrupting ligand binding Head & neck
C423F EGF11 Disrupting Notch folding or causing cysteine crosslink Cutaneous
E424K EGF11 Disrupting ligand binding Esophagus, Head & neck
C429Y EGF11 Disrupting Notch folding or causing cysteine crosslink Head & neck
C429S EGF11 Disrupting Notch folding or causing cysteine crosslink Lung
G434C EGF11 Disrupting calcium binding or causing cysteine crosslink Cervical
C440F/R EGF11 Disrupting Notch folding or causing cysteine crosslink Head & neck
N454T EGF12 Disrupting calcium binding Head & neck
E455K EGF12 Disrupting calcium binding Head & neck
P460L EGF12 Substituting conserved residue of EGF module Esophagus
C461Y EGF12 Disrupting Notch folding or causing cysteine crosslink Head & neck
A465T EGF12 Disrupting ligand binding Esophagus, Head & neck
C467Y EGF12 Disrupting Notch folding or causing cysteine crosslink Cervical
D469G EGF12 Disrupting ligand binding or calcium binding Cutaneous
C478F EGF12 Disrupting Notch folding or causing cysteine crosslink Cutaneous
C478S/Y EGF12 Disrupting Notch folding or causing cysteine crosslink Head & neck
G481S EGF12 Benign Head & neck
G481C EGF12 Causing cysteine crosslink Head & neck
G484V EGF12 Benign Esophagus, Head & neck
C1068Y EGF28 Disrupting Notch folding or causing cysteine crosslink Cervical
C1085Y/W EGF28 Disrupting Notch folding or causing cysteine crosslink Head & neck
NRR
W1487C LNR- B Disrupting Notch folding or causing cysteine crosslink Cervical
D1517N LNR- B Disrupting calcium binding or Notch folding Cutaneous, Head & neck
R1520H LNR- B Disrupting calcium binding or Notch folding Head & neck
R1523C LNR- B Causing cysteine crosslink Cervical
C1561Y LNR- C Disrupting Notch folding or causing cysteine crosslink Cervical
R1594Q LNR- C Stabilizing the inhibitory state of NRR Cutaneous
S1651L HD Benign Cervical
RAM- ANK
P1770S RAM Decreasing transcription factor binding; Cutaneous
R1784L RAM Benign Lung
N1809H RAM Benign Cutaneous
N1875K ANK Benign Head & neck
T1996M ANK Interfering with transcription factor binding Head & neck
D2020H ANK Disrupting Notch folding or changing ANK conformation Lung
A2023T ANK Disrupting Notch folding or changing ANK conformation Head & neck
V2038L ANK Interfering with transcription factor binding Lung
P2064L ANK Disrupting Notch folding or changing ANK conformation Head & neck
The missense mutants are from the analysis of Figure 3B- F. Only mutations identified in ligand- binding region EGF11- 13, EGF28, NRR domain, and 
RAM- ANK region are listed and analyzed.
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between HNSCC and CSCC, implicating that Notch may 
be tumor suppressive in HNSCC as that in CSCC. This 
concept may need to be further validated with the studies 
targeting SCCs from other tissues, such as lung and cervical 
whose molecular pathogenesis remains poorly understood. 
However, the oncogenic role of Notch in HNSCC is likely, 
as the increased levels of Notch signaling components in 
OSCC/ESCC were reported [82, 84, 85], although their 
biological consequences remain to be determined.
A tumor suppressor such as NOTCH is a possible, but 
challenging therapeutic target [96]. Therefore, current treat-
ments of SCC are directed toward upstream regulators and 
downstream effectors of the Notch pathway, which has been 
extensively studied and well reviewed for CSCC [97]. New 
understanding of Notch signaling may lead to therapeutic 
development for less- characterized SCC types. Notably, 
structure- guided analysis of the functional consequences 
of NOTCH cancer mutations, as we present in this review, 
may provide new clues and advance the development of 
drugs that can restore aberrant Notch signaling. This strat-
egy was proved to be applicable for another tumor sup-
pressor, p53[98, 99], and therefore may represent an 
attractive future direction of targeted therapy of SCC. 
Emerging new understanding of the Notch pathway in 
diverse SCC types will likely enhance the possibility for 
improvement in therapy of SCC.
Moreover, besides at the levels of mRNA and protein 
levels, Notch activation can be regulated at other different 
levels such as ligand binding, protease cleavage, or even 
post- translational modifications. It may be fruitful to target 
this broader Notch pathway to gain a more panoramic 
understanding of the important role of Notch in SCCs. A 
nice example is a recent research on the tumor suppressor 
role of Notch pathway in bladder cancer, revealed by the 
characterization of multiple components of Notch pathway 
[100]. We have recently characterized a Notch- modifying 
enzyme Xxylt1 [101] that is frequently amplified in specific 
cancer types lacking loss- of- function XXYLT1 mutations. 
Surprisingly, of the six cancer types with highest XXYLT1 
amplification frequency, three are squamous cell carcino-
mas: SCCs of head and neck, lung, and cervical. Considering 
that Xxylt1 can negatively regulate Notch activation [102], 
this may suggest a novel pathway changes to comprise Notch 
activation in the tumorigenesis of these cancer types. 
Therefore, considering the complex roles of NOTCH in 
tumorigenesis, expanding our knowledge of Notch pathway 
will surely benefit our understanding of the complicated 
Notch in cancer.
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